A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

AbbVie

Status and phase: Completed; Phase 4

Conditions: Anxiety Disorders,Generalized Anxiety Disorder

Treatments: Drug: Escitalopram; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03924323

SCT-MD-60

Details and patient eligibility

About

This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD. Participating minors will be assigned to receive either the study drug escitalopram or a pill without any drug in it called a placebo. The purpose of this research is to study the safety and effectiveness of escitalopram in minors with GAD.

Enrollment: 273 patients

Sex: All

Ages: 7 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject's parent/legal representative must give written informed consent, including privacy authorization, prior to study participation. The subject will complete an informed assent prior to study participation.
• Subject meets DSM-5 criteria for a primary diagnosis of GAD at screening established by a comprehensive psychiatric evaluation and confirmed/supported using the Mini-International Neuropsychiatric Interview for children and adolescents (MINI Kid).
• Male subjects who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 14 days after the last dose of study drug.
• Female subjects who are sexually active and are of childbearing potential must use, with their partner, an approved method of highly effective contraception from the time of informed consent until 14 days after the last dose of study drug.
• Female subjects who are not of childbearing potential do not need to use any methods of contraception. This includes preadolescent and adolescent females who have not reached menarche. - Subject must have venous access enough to allow blood sampling and be compliant with blood draws as per the protocol.

Exclusion criteria

• Current diagnosis of MDD, attention-deficit/hyperactivity disorder, or lifetime diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, feeding and/or eating disorder, obsessive-compulsive disorder, conduct disorder, oppositional defiant disorder, post-traumatic stress disorder, panic disorder, or pervasive development disorder.
• Suspected or previously diagnosed intellectual disability disorder.
• One or more first-degree relatives with diagnosed bipolar I disorder.
• History of seizure disorder (other than febrile seizures).
• History of electroconvulsive therapy at any time during the subject's lifetime.
• Known hypersensitivity to escitalopram (escitalopram oxalate) or citalopram or any of the inactive ingredients or had frequent or severe allergic reactions to multiple medications.
• Taking any medications that are contraindicated to escitalopram (escitalopram oxalate).
• Inability to speak, read, or understand English well enough to complete the assessments.
• No active suicidal ideation or lifetime history of suicidal behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

273 participants in 2 patient groups, including a placebo group

Escitalopram 10 mg/day

Experimental group

Description:

Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion

Treatment:

Drug: Escitalopram

Placebo

Placebo Comparator group

Description:

Matching oral administration of placebo once daily

Treatment:

Other: Placebo